Latest News

The ASPIRED trial found immediate ECG monitoring in the ED did not reduce recurrent syncope but doubled arrhythmia detection and cut mortality.

The phase 2a study found TEV '408 significantly reduced intestinal damage and inflammation versus placebo at week 8

The HCPLive editorial team previews late-breaking abstracts across COPD, asthma, IPF, PAH, and AATD ahead of ERS Congress 2026 in Barcelona.

A pediatric hematologist unpacks why sickle cell disease burden, treatment access, and pain outcomes differ across sub-Saharan Africa, other LMICs, and HICs.

Stacey Rifkin-Zenenberg, DO, marks Sickle Cell Disease Awareness Month with insight on gene therapy vs. transplant.

A regulatory resubmission, 2 phase 3 psychedelic trial readouts, new TMS dosing data, and an MDD genetics study, all in this August 2026 recap.

FDA actions, a WAO consensus update, and late-stage trial data in food allergy, anaphylaxis, CRSwNP, and EoE, all in this August 2026 recap.

A nephrologist outlines gaps in CKD tracking, medication access, and transplant standards across the carceral health system.

New RCT finds ketogenic diet cuts liver fat and improves glycemic control more than Mediterranean or plant-forward diets after matched weight loss.

The investigational therapy did not achieve statistical significance in KCCQ-TSS or in 6MWD, but saw substantial changes in exploratory secondary endpoints.

H-ISDN missed its primary endpoint in H-HeFT, but a pooled meta-analysis found significant reductions in all-cause and cardiovascular death in HFrEF.

The China Rural Hypertension Control Program found a non-physician-led intensive blood pressure intervention reduced dementia risk by 15% over 7 years.

EPIDAURUS stopped early after potent P2Y12 inhibitors plus a DOAC raised bleeding without reducing ischemic events in patients with AF and MI.

ACASA-TAVI found NOAC monotherapy cut subclinical leaflet thrombosis nearly in half versus aspirin after TAVI, meeting safety noninferiority.

CMR GUIDE found ICD implantation did not significantly reduce sudden cardiac death or dangerous arrhythmia versus a loop recorder in LVEF 36-50%.

Phase 2b LUMINARA results showed the oral relaxin agonist AZD5462 improved echocardiographic measures of cardiac function in patients with chronic heart failure.

The Met-HeFT trial and a companion meta-analysis found metformin did not significantly improve cardiovascular outcomes in patients with HFrEF.

A roundup of the top cardiology news out of ESC Congress2026 on day 2, spanning primary prevention, novel therapies, and antibiotic stewardship.

New MILOS data show bempedoic acid-based therapy translated to meaningful reductions in predicted 10-year cardiovascular risk.

The REACT study found silent atherosclerosis in 57.1% of adults without known cardiovascular disease, a burden largely missed by the SCORE2 risk tool.

A longitudinal survey found PSVT disrupts patients' daily activities, sleep, and emotions between episodes.

Despite failing to display a clinically significant reduction in all-cause death or hospitalization for cardiovascular events, the trial did highlight evolocumab’s LDL-C-lowering capacity.

CTX310, a CRISPR-Cas9 therapy targeting ANGPTL3, sustained deep LDL and triglyceride reductions at 1 year after a single infusion, per ESC 2026 data.